Entering text into the input field will update the search result below

Mustang Bio: The Market Is Missing This Opportunity

May 03, 2022 3:54 PM ETMustang Bio, Inc. (MBIO)11 Comments


  • Last year was a productive year for Mustang Bio as they advanced the company’s cell and gene therapies deeper into clinical development.
  • Recent figures from their CAR-T programs have revealed striking results that indicate potential cures for hematologic cancers and solid tumors.
  • I believe the market is overlooking MBIO, and the share price has fallen below $1 per share.
  • I am finding a spot for MBIO in my Seeking Alpha Marketplace Service, Compounding Healthcare.
  • This idea was discussed in more depth with members of my private investing community, Compounding Healthcare. Learn More »

Dendritic Cell activate T cells, trigger immune responses, they are responsible of cells protection of the body.

Design Cells/iStock via Getty Images

Mustang Bio (NASDAQ:MBIO) had a productive 2021 as they progressed the company's cell and gene therapies deeper into clinical development. However, recent data from their CAR-T programs has revealed impressive results that point to potential cures

Mustang Bio Pipeline

Mustang Bio Pipeline (Mustang Bio)

MBIO Revenue Estimates

MBIO Revenue Estimates (Seeking Alpha)

MBIO Daily Chart

MBIO Daily Chart (Trendspider)

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare, and sign up for a free trial.

This article was written by

Biologics profile picture
Diagnosing the market to compound capital in the healthcare sector.

After years of working in the medical field, I have developed a passion for biotech and lifesaving therapies. Now, I am a full-time healthcare investor who is in search of the next breakthrough therapy, device, or pharmaceutical. My trade focus is around catalysts and potential acquisitions. In addition, I provide a marketplace service, Compounding Healthcare through Seeking Alpha.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MBIO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.